BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Cantor Global Healthcare Conference 2025 September 4, 2025 9:45 AM EDT
Company Participants
Charles Gayer – President
Babar Ghias – CFO & Head of Corporate Development
Conference Call Participants
Steven Seedhouse – Cantor Fitzgerald & Co., Research Division
Presentation
Steven Seedhouse
MD & Biotechnology Analyst
Good morning, everyone, and thanks so much for joining us for our next session. I’m Steve Seedhouse with the Cantor Biotech team. It’s really a privilege to welcome our next participating company at the conference, BioCryst Pharmaceuticals. Thanks to everyone on the webcast and in the room for being here also.
And I’m joined on stage by CFO, Babar Ghias and President and CCO, excuse me. And I guess there’s a lot of change in the title. So we’ll say emerging CEO as well, Charlie Gayer. Thanks so much for being here. We would love to pass the mic over and just ask for an intro to BioCryst, current state of affairs, outlook for the rest of the year for some opening comments, and then we’ll dive right into Q&A.
Charles Gayer
President
Sure. Thanks, Steve. We’re really pleased to be here. Babar and I will be making some forward-looking statements. Those statements have risks. You can find those risks in our SEC filings at bioocryst.com.
BioCryst is in a really exciting place right now, and I’m excited to be taking over CEO in January because we have ORLADEYO, which is going to sell $580 million to $600 million globally this year and is growing at about a 20% CAGR. We are in the process of actually selling our European business, which will close early in October, and that’s going to give us an opportunity. That’s actually a business that, while commercially was going very well, was not profitable for us. And so the $250 million we get from that deal is going to
#BioCryst #Pharmaceuticals #BCRX #Presents #Cantor #Global #Healthcare #Conference